Piqray vs. Verzenio
Are Piqray and Verzenio the Same Thing?
Piqray (alpelisib) and Verzenio (abemaciclib) are kinase inhibitors indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Verzenio is also used as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Side effects of Piqray and Verzenio that are similar include diarrhea, rash, nausea, fatigue, decreased appetite, inflammation of the mouth and lips, vomiting, weight loss, hair loss, abdominal pain, swelling of extremities, fever, changes in taste, headache, itching, and increased alanine aminotransferase.
Side effects of Piqray that are different from Verzenio include indigestion, dry nose, urinary tract infection (UTI), dry skin, prolonged aPTT, and laboratory abnormalities (increased or decreased blood sugar, increased creatinine, decreased lymphocyte count, increased GGT, decreased hemoglobin, increased lipase, and decreased calcium).
Side effects of Verzenio that are different from Piqray include low white blood cell count (neutropenia, leukopenia), infections, anemia, low blood platelet count (thrombocytopenia), cough, dizziness, and increased aspartate aminotransferase.
Both Piqray and Verzenio may interact with strong CYP3A inducers.
Piqray may also interact with BCRP inhibitors, warfarin, and acid reducing agents.
Verzenio may also interact with ketoconazole and other strong CYP3A inhibitors and grapefruit.
What Are Possible Side Effects of Piqray?
Side effects of Piqray include:
- diarrhea
- rash
- nausea
- fatigue
- decreased appetite
- inflammation of the mouth and lips
- vomiting
- weight loss
- hair loss
- abdominal pain
- indigestion
- swelling of extremities
- fever
- dry nose
- urinary tract infection (UTI)
- changes in taste
- headache
- itching
- dry skin
- prolonged aPTT
- and laboratory abnormalities (increased or decreased blood sugar
- increased creatinine
- decreased lymphocyte count
- increased GGT
- increased ALT
- decreased hemoglobin
- increased lipase
- and decreased calcium)
What Are Possible Side Effects of Verzenio?
Common side effects of Verzenio include:
- diarrhea,
- low white blood cell count (neutropenia, leukopenia),
- nausea,
- abdominal pain,
- infections,
- fatigue,
- anemia,
- decreased appetite,
- vomiting,
- headache,
- low blood pla telet count (thrombocytopenia),
- sores and inflammation inside the mouth,
- swelling of extremities,
- fever,
- cough,
- hair loss,
- itching,
- rash,
- changes in taste,
- dizziness,
- alanine aminotransferase increased,
- aspartate aminotransferase increased,
- and weight loss.
What Is Piqray?
Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
What Is Verzenio?
Verzenio (abemaciclib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; and as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
What Drugs Interact With Piqray?
Piqray may interact with CYP3A4 inducers, BCRP inhibitors, warfarin, and acid reducing agents. Tell your doctor all medications and supplements you use. Piqray is not recommended for use during pregnancy; it may harm a fetus. Piqray is used in combination with fulvestrant, which may also harm a fetus. It is unknown if Piqray passes into breast milk. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment with Piqray and for 1 week after the last dose.
What Drugs Interact With Verzenio?
Verzenio may interact with:
- ketoconazole and other strong CYP3A inhibitors,
- grapefruit, and
- rifampin and other strong CYP3A inducers
Tell your doctor all medications and supplements you use.